Tag: Liver disease
TARGET PharmaSolutions And Gilead Sciences Take Aim At Liver Disease
TARGET PharmaSolutions, Inc., has announced that it has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. Gilead is the sixth partner in TARGET-NASH, joining Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Intercept and Novartis, and the first partner...
Biobanking Science: Growing Liver Organoids From Tumor Biopsies
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and causes over 700,000 deaths each year (1). The number of HCC cases has dramatically risen over the past two decades due to an increase in infectious hepatitis,...
Sekisui XenoTech Research Biobank Adds Fatty Liver Disease Assets
Sekisui XenoTech, LLC is a global Contract Research Organization (CRO). Established for almost 25 years, the company offers an ever-evolving selection of cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADME Tox and pharmacology, in vivo ADME...
Regeneron Confirms New Chronic Liver Disease Drug Target Using Biobank Data
For the first time Regeneron has reported a variant in the HSD17B13 gene that is associated with reduced risk of, in other words protection from, various chronic liver diseases for which there are currently no approved therapeutics . The...
